BILL ANALYSIS
AB 1733
Page 1
Date of Hearing: April 21, 2010
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Felipe Fuentes, Chair
AB 1733 (Hill) - As Introduced: February 4, 2010
Policy Committee: Health Vote:18-0
Business & Professions 11-0
Urgency: No State Mandated Local Program:
No Reimbursable: No
SUMMARY
This bill requires the governor to establish the position of
Director of California Biotechnology Retention and Recruitment
(Director) within the Governor's Office. Requires the Director
to serve as a regulatory and informational resource to companies
within California and to provide support to companies outside
the state that are interested in relocating to California.
Requires the position to be funded within existing resources.
FISCAL EFFECT
1)Annual GF costs in the range of $300,000 to support a high
level staff member conversant in biotechnology generally and
life science regulatory affairs specifically, including
expertise in garnering support of companies from outside of
California. This cost estimate includes a half-time support
staff and a travel budget to support out-of-state travel.
2)This bill specifies that the Director will be hired from
within existing resources. The Governor's Office, like many
state agencies has been subject to a 15% reduction in wages
and time worked, per executive furlough orders. It is unclear
there are any existing resources to be dedicated to the
workload established in this bill.
COMMENTS
Rationale . This bill establishes a high-level position within
the Governor's Office to foster the growth of California's
biotechnology industry through increased collaboration between
state government, universities, and private sector companies.
AB 1733
Page 2
California is home to over 2,000 biomedical companies. However,
according to the author, recent industry surveys show a
significant portion of companies are considering moving
manufacturing out-of-state. In addition to cost pressures for
companies operating in California, nations such as China and
Ireland are offering specific incentives for companies to
relocate overseas. The position established in this bill will
increase statewide focus on maintaining and increasing the
amount of biomedical business activity in California.
Analysis Prepared by : Mary Ader / APPR. / (916) 319-2081